JPH08510900A - 改良された抗インフルエンザ活性を有する修飾オリゴヌクレオチド - Google Patents

改良された抗インフルエンザ活性を有する修飾オリゴヌクレオチド

Info

Publication number: JPH08510900A
Authority: JP; Japan
Prior art keywords: influenza; oligonucleotide; region; gene; phosphorothioate
Prior art date: 1993-03-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP6522317A

Other languages

English (en)

Japanese (ja)

Inventor

アグラワル、スディール

タン、ジン−ヤン

パドマプリヤ、アベイシンゲ

Original Assignee

ハイブライドンインコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-31

Filing date

1994-03-30

Publication date

1996-11-19

1994-03-30 Application filed by ハイブライドンインコーポレイテッド filed Critical ハイブライドンインコーポレイテッド

1996-11-19 Publication of JPH08510900A publication Critical patent/JPH08510900A/ja

Status Pending legal-status Critical Current

Links

206010022000 influenza Diseases 0.000 title claims abstract description 118
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title claims abstract description 60
230000000694 effects Effects 0.000 title description 12
108091034117 Oligonucleotide Proteins 0.000 claims abstract description 197
241000712461 unidentified influenza virus Species 0.000 claims abstract description 30
239000002773 nucleotide Substances 0.000 claims description 76
125000003729 nucleotide group Chemical group 0.000 claims description 72
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 57
150000007523 nucleic acids Chemical group 0.000 claims description 36
239000002336 ribonucleotide Substances 0.000 claims description 30
108091028043 Nucleic acid sequence Proteins 0.000 claims description 28
108091028664 Ribonucleotide Proteins 0.000 claims description 28
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical group [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims description 24
125000002652 ribonucleotide group Chemical group 0.000 claims description 24
108090000623 proteins and genes Proteins 0.000 claims description 22
238000000034 method Methods 0.000 claims description 20
-1 carboxymethyl ester Chemical class 0.000 claims description 19
239000005547 deoxyribonucleotide Substances 0.000 claims description 19
125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 19
230000000295 complement effect Effects 0.000 claims description 18
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 16
125000005600 alkyl phosphonate group Chemical group 0.000 claims description 8
101710154606 Hemagglutinin Proteins 0.000 claims description 7
108010061100 Nucleoproteins Proteins 0.000 claims description 7
101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 7
101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 7
101710176177 Protein A56 Proteins 0.000 claims description 7
108060003393 Granulin Proteins 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 6
238000004806 packaging method and process Methods 0.000 claims description 6
102000004190 Enzymes Human genes 0.000 claims description 5
108090000790 Enzymes Proteins 0.000 claims description 5
239000000203 mixture Substances 0.000 claims description 5
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims description 4
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 3
108010006232 Neuraminidase Proteins 0.000 claims description 3
150000004651 carbonic acid esters Chemical class 0.000 claims description 3
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims description 3
NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 claims description 3
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 3
150000003457 sulfones Chemical class 0.000 claims description 3
150000003568 thioethers Chemical class 0.000 claims description 3
125000003158 alcohol group Chemical group 0.000 claims description 2
101150084750 1 gene Proteins 0.000 claims 5
101150028074 2 gene Proteins 0.000 claims 5
101150090724 3 gene Proteins 0.000 claims 5
230000035931 haemagglutination Effects 0.000 claims 1
FUWGSUOSJRCEIV-UHFFFAOYSA-N phosphonothioic O,O-acid Chemical group OP(O)=S FUWGSUOSJRCEIV-UHFFFAOYSA-N 0.000 claims 1
230000010076 replication Effects 0.000 abstract description 11
101710163270 Nuclease Proteins 0.000 abstract description 5
150000004713 phosphodiesters Chemical class 0.000 description 15
230000015556 catabolic process Effects 0.000 description 13
238000006731 degradation reaction Methods 0.000 description 13
201000007224 Myeloproliferative neoplasm Diseases 0.000 description 12
239000000074 antisense oligonucleotide Substances 0.000 description 12
238000012230 antisense oligonucleotides Methods 0.000 description 12
241000700605 Viruses Species 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
238000003786 synthesis reaction Methods 0.000 description 11
210000004027 cell Anatomy 0.000 description 10
239000005289 controlled pore glass Substances 0.000 description 10
108020004999 messenger RNA Proteins 0.000 description 9
239000000178 monomer Substances 0.000 description 9
150000001875 compounds Chemical class 0.000 description 8
108020004707 nucleic acids Proteins 0.000 description 8
102000039446 nucleic acids Human genes 0.000 description 8
108010062513 snake venom phosphodiesterase I Proteins 0.000 description 8
239000000126 substance Substances 0.000 description 8
108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
108020000948 Antisense Oligonucleotides Proteins 0.000 description 7
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
230000008878 coupling Effects 0.000 description 7
238000010168 coupling process Methods 0.000 description 7
238000005859 coupling reaction Methods 0.000 description 7
239000002777 nucleoside Substances 0.000 description 7
239000011593 sulfur Substances 0.000 description 7
229910052717 sulfur Inorganic materials 0.000 description 7
238000012360 testing method Methods 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
230000000120 cytopathologic effect Effects 0.000 description 6
239000002609 medium Substances 0.000 description 6
231100000419 toxicity Toxicity 0.000 description 6
230000001988 toxicity Effects 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
150000003833 nucleoside derivatives Chemical class 0.000 description 5
229940046166 oligodeoxynucleotide Drugs 0.000 description 5
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical group CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108010068698 spleen exonuclease Proteins 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
108020004414 DNA Proteins 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
229930182566 Gentamicin Natural products 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
WXJXBKBJAKPJRN-UHFFFAOYSA-N Methanephosphonothioic acid Chemical group CP(O)(O)=S WXJXBKBJAKPJRN-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
229960002518 gentamicin Drugs 0.000 description 3
239000000185 hemagglutinin Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 3
231100001274 therapeutic index Toxicity 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
230000029812 viral genome replication Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
108060002716 Exonuclease Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
102000005348 Neuraminidase Human genes 0.000 description 2
102000011931 Nucleoproteins Human genes 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
150000004985 diamines Chemical class 0.000 description 2
230000029087 digestion Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
102000013165 exonuclease Human genes 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
MZDMEAKVGTZHES-UHFFFAOYSA-N methylphosphonamidous acid Chemical class CP(N)O MZDMEAKVGTZHES-UHFFFAOYSA-N 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
230000004660 morphological change Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
125000003835 nucleoside group Chemical group 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000004445 quantitative analysis Methods 0.000 description 2
238000000611 regression analysis Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
239000002342 ribonucleoside Substances 0.000 description 2
239000000523 sample Substances 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
238000011282 treatment Methods 0.000 description 2
JUDOLRSMWHVKGX-UHFFFAOYSA-N 1,1-dioxo-1$l^{6},2-benzodithiol-3-one Chemical compound C1=CC=C2C(=O)SS(=O)(=O)C2=C1 JUDOLRSMWHVKGX-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000282465 Canis Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
241001327708 Coriaria sarmentosa Species 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
241000712431 Influenza A virus Species 0.000 description 1
241001500351 Influenzavirus A Species 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
101710203526 Integrase Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
TTZMPOZCBFTTPR-UHFFFAOYSA-N O=P1OCO1 Chemical compound O=P1OCO1 TTZMPOZCBFTTPR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
241000207961 Sesamum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
241000282887 Suidae Species 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
CCAZWUJBLXKBAY-ULZPOIKGSA-N Tutin Chemical compound C([C@]12[C@@H]3O[C@@H]3[C@@]3(O)[C@H]4C(=O)O[C@@H]([C@H]([C@]32C)O)[C@H]4C(=C)C)O1 CCAZWUJBLXKBAY-ULZPOIKGSA-N 0.000 description 1
229940117913 acrylamide Drugs 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
150000001345 alkine derivatives Chemical class 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000005549 deoxyribonucleoside Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
CDPKWOKGVUHZFR-UHFFFAOYSA-N dichloro(methyl)phosphane Chemical compound CP(Cl)Cl CDPKWOKGVUHZFR-UHFFFAOYSA-N 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
235000019439 ethyl acetate Nutrition 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000001036 exonucleolytic effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
230000009422 growth inhibiting effect Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000037797 influenza A Diseases 0.000 description 1
108010064513 influenza virus polymerase basic protein 1 Proteins 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000003607 modifier Substances 0.000 description 1
ORHCCKAXBZQHGB-UHFFFAOYSA-N n-[chloro(methyl)phosphanyl]-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)P(C)Cl ORHCCKAXBZQHGB-UHFFFAOYSA-N 0.000 description 1
WLFFOHVSESNIFH-UHFFFAOYSA-N n-phosphanylpropan-1-amine Chemical compound CCCNP WLFFOHVSESNIFH-UHFFFAOYSA-N 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
239000012857 radioactive material Substances 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000011218 segmentation Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
230000005476 size effect Effects 0.000 description 1
239000003998 snake venom Substances 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
238000006177 thiolation reaction Methods 0.000 description 1
GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Pulmonology (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

JP6522317A 1993-03-31 1994-03-30 改良された抗インフルエンザ活性を有する修飾オリゴヌクレオチド Pending JPH08510900A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US4075293A	1993-03-31	1993-03-31
US08/040,752		1993-03-31
PCT/US1994/003454 WO1994023028A2 (fr)	1993-03-31	1994-03-30	Oligonucleotides modifies ayant une activite antigrippe amelioree

Publications (1)

Publication Number	Publication Date
JPH08510900A true JPH08510900A (ja)	1996-11-19

Family

ID=21912738

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP6522317A Pending JPH08510900A (ja)	1993-03-31	1994-03-30	改良された抗インフルエンザ活性を有する修飾オリゴヌクレオチド

Country Status (7)

Country	Link
EP (1)	EP0693123A1 (fr)
JP (1)	JPH08510900A (fr)
CN (1)	CN1124980A (fr)
AU (1)	AU6527094A (fr)
CA (1)	CA2159350A1 (fr)
NZ (1)	NZ263985A (fr)
WO (1)	WO1994023028A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE733059T1 (de) *	1993-12-09	1997-08-28	Univ Jefferson	Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
US6608035B1 (en) *	1994-10-25	2003-08-19	Hybridon, Inc.	Method of down-regulating gene expression
US6645943B1 (en)	1994-10-25	2003-11-11	Hybridon, Inc.	Method of down-regulating gene expression
AU5325696A (en) *	1995-04-03	1996-10-23	Hybridon, Inc.	Method of modulating gene expression without depleting compl ement
US6372427B1 (en)	1995-04-12	2002-04-16	Hybridon, Inc.	Cooperative oligonucleotides
WO1997038097A1 (fr) *	1995-04-12	1997-10-16	Hybridon, Inc.	Oligonucleotides cooperatifs
GB9511720D0 (en) *	1995-06-09	1995-08-02	Isis Innovation	Oligonucleotide phosphorylation method and products
US7074768B2 (en)	1995-08-17	2006-07-11	Idera Pharmaceuticals, Inc.	Modified protein kinase A-specific oligonucleotides and methods of their use
US5652356A (en) *	1995-08-17	1997-07-29	Hybridon, Inc.	Inverted chimeric and hybrid oligonucleotides
US6624293B1 (en)	1995-08-17	2003-09-23	Hybridon, Inc.	Modified protein kinase A-specific oligonucleotides and methods of their use
US5969117A (en) *	1995-08-17	1999-10-19	Hybridon, Inc.	Modified protein kinase a-specific oligonucleotide
US5886165A (en) *	1996-09-24	1999-03-23	Hybridon, Inc.	Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US5989912A (en)	1996-11-21	1999-11-23	Oligos Etc. Inc.	Three component chimeric antisense oligonucleotides
WO1998040479A1 (fr) *	1997-03-12	1998-09-17	Hybridon, Inc.	Oligonucleotides modifies specifiques de la proteine kinase a et methodes d'utilisation
GB9710044D0 (en) *	1997-05-16	1997-07-09	Innes John Centre Innov Ltd	A plant disease resistance signalling gene: materials and methods relating thereto
ATE556714T1 (de)	2002-02-01	2012-05-15	Life Technologies Corp	Doppelsträngige oligonukleotide
US20060009409A1 (en)	2002-02-01	2006-01-12	Woolf Tod M	Double-stranded oligonucleotides
WO2007053696A2 (fr) *	2005-11-01	2007-05-10	Alnylam Pharmaceuticals, Inc.	Inhibition de la replication du virus de la grippe par interference arn
CA2715289C (fr)	2008-02-11	2019-12-24	Rxi Pharmaceuticals Corporation	Polynucleotides d'arni modifies et leurs utilisations
EP2342340A1 (fr)	2008-09-22	2011-07-13	Rxi Pharmaceuticals Corporation	Emploi d'arni dans des applications dermatologiques
WO2010059226A2 (fr)	2008-11-19	2010-05-27	Rxi Pharmaceuticals Corporation	Inhibition de map4k4 via arni
WO2010078536A1 (fr)	2009-01-05	2010-07-08	Rxi Pharmaceuticals Corporation	Inhibition de pcsk9 par arni
US9745574B2 (en)	2009-02-04	2017-08-29	Rxi Pharmaceuticals Corporation	RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
RU2615143C2 (ru)	2010-03-24	2017-04-04	Адвирна	Самодоставляющие PHKi соединения уменьшенного размера
EP3560503B1 (fr)	2010-03-24	2021-11-17	Phio Pharmaceuticals Corp.	Interférence d'arn dans des indications dermiques et fibrotiques
CN103200945B (zh)	2010-03-24	2016-07-06	雷克西制药公司	眼部症候中的rna干扰
CN106061488B (zh)	2013-12-02	2021-04-09	菲奥医药公司	癌症的免疫治疗
CN105960265A (zh)	2013-12-04	2016-09-21	阿克赛医药公司	利用经化学修饰的寡核苷酸处理伤口愈合的方法
WO2015168108A2 (fr)	2014-04-28	2015-11-05	Rxi Pharmaceuticals Corporation	Procédés de traitement du cancer au moyen d'un acide nucléique deciblage de mdm2 ou mycn
US10900039B2 (en)	2014-09-05	2021-01-26	Phio Pharmaceuticals Corp.	Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
EP3862005A1 (fr)	2015-07-06	2021-08-11	Phio Pharmaceuticals Corp.	Molécules d'acide nucléique ciblant la superoxyde dismutase 1 (sod1)
US10808247B2 (en)	2015-07-06	2020-10-20	Phio Pharmaceuticals Corp.	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
WO2017070151A1 (fr)	2015-10-19	2017-04-27	Rxi Pharmaceuticals Corporation	Composés d'acides nucléiques de taille réduite à auto-administration ciblant des longs arn non codants
US12544344B2 (en)	2017-04-19	2026-02-10	Phio Pharmaceuticals Corp.	Topical delivery of nucleic acid compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5194428A (en) *	1986-05-23	1993-03-16	Worcester Foundation For Experimental Biology	Inhibition of influenza virus replication by oligonucleotide phosphorothioates
DE3907562A1 (de) *	1989-03-09	1990-09-13	Bayer Ag	Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung
US5149797A (en) *	1990-02-15	1992-09-22	The Worcester Foundation For Experimental Biology	Method of site-specific alteration of rna and production of encoded polypeptides
HUT69956A (en) *	1990-08-14	1995-09-28	Isis Pharmaceuticals Inc	Methode for inhibition of influenza virus by antiseuse oligonucleotides

1994
- 1994-03-30 NZ NZ263985A patent/NZ263985A/en unknown
- 1994-03-30 CA CA002159350A patent/CA2159350A1/fr not_active Abandoned
- 1994-03-30 EP EP94912901A patent/EP0693123A1/fr not_active Withdrawn
- 1994-03-30 CN CN94192300A patent/CN1124980A/zh active Pending
- 1994-03-30 AU AU65270/94A patent/AU6527094A/en not_active Abandoned
- 1994-03-30 WO PCT/US1994/003454 patent/WO1994023028A2/fr not_active Ceased
- 1994-03-30 JP JP6522317A patent/JPH08510900A/ja active Pending

Also Published As

Publication number	Publication date
AU6527094A (en)	1994-10-24
CA2159350A1 (fr)	1994-10-13
WO1994023028A2 (fr)	1994-10-13
EP0693123A1 (fr)	1996-01-24
CN1124980A (zh)	1996-06-19
NZ263985A (en)	1997-07-27
WO1994023028A3 (fr)	1995-02-16

Publication	Publication Date	Title
JPH08510900A (ja)	1996-11-19	改良された抗インフルエンザ活性を有する修飾オリゴヌクレオチド
JP6959293B2 (ja)	2021-11-02	Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法
AU678769B2 (en)	1997-06-12	Oligonucleotide alkylphosphonothioates
US6489464B1 (en)	2002-12-03	Branched oligonucleotides as pathogen-inhibitory agents
EP0677056B1 (fr)	1996-05-22	Alkylphosphonates et alkylphosphonothioates d'oligonucleotides
EP0650493B1 (fr)	2000-12-13	Phosphorothioates d'oligonucleotides hybrides
JPH08501928A (ja)	1996-03-05	治療剤としての自己安定化オリゴヌクレオチド
JP2003012688A (ja)	2003-01-15	オリゴヌクレオチドｎ３’→ｐ５’ホスホルアミデート：合成および化合物；ハイブリダイゼーションおよびヌクレアーゼ耐性特性
CN104673795A (zh)	2015-06-03	用于抑制基因表达的组合物及其用途
JP2002541825A (ja)	2002-12-10	ユニバーサル及び／又は同義性塩基を含むアンチセンスオリゴヌクレオチド
KR20020033744A (ko)	2002-05-07	사람 ｅｇ5의 발현을 억제하는 올리고뉴클레오티드
CN104321334A (zh)	2015-01-28	三环核苷及由其制备的低聚化合物
JP3855117B2 (ja)	2006-12-06	組合せアンチセンス・ライブラリー
CN121057820A (zh)	2025-12-02	使用环状前药核酸递送rna治疗药物
HK40061440A (zh)	2022-06-02	用於抑制乙型肝炎病毒的基因表达的组合物和方法